Search International and National Patent Collections
|1. (WO2018126897) APPLICATION OF SODIUM 5-BROMO-2-(α-HYDROXYPENTYL) BENZOATE IN DRUGS TREATING CARDIOVASCULAR DISEASE|
|Applicants:||ZHENG ZHOU UNIVERSITY
HENAN METAB BIOPHARMA CO.,LTD
SONG, Chuan Jun
|Title:||APPLICATION OF SODIUM 5-BROMO-2-(α-HYDROXYPENTYL) BENZOATE IN DRUGS TREATING CARDIOVASCULAR DISEASE|
Disclosed is an application of sodium 5-bromo-2-(α-hydroxypentyl) benzoate (BZP) in drugs treating cardiovascular disease, belonging to the field of pharmaceutical chemistry. Experiments show that BZP has a protective effect with regard to acute and chronic myocardial ischaemia-reperfusion injury in mice, BZP oral administration and intravenous injection reduce animal overall acute myocardial infarction areas, and BZP reduces isolated perfused heart acute ischaemia-reperfusion injury myocardial infarction areas in mice, thereby improving myocardial contractile function and reducing haematological myocardial injury markers. In addition, BZP chronic oral administration delays the progress of cardiac hypertrophy changing to heart failure after acute myocardial infarction in mice, reduces ventricular remodelling caused by ischaemic heart disease in mice, and significantly improves heart function treatment effects. Furthermore, BZP temporarily reduces the blood pressure of hypertensive rats (SHR rats). These effects show that BZP has effective clinical research and development prospects for drugs protecting against acute and chronic myocardial infarction myocardial injury.